v3.26.1
Debt Financing - Royalty Note Purchase Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Jul. 17, 2026
Jun. 30, 2026
Jun. 30, 2025
Line of Credit Facility [Line Items]      
Proceeds from the issuance of ordinary shares   $ 128,207 $ 9,915
Securities Purchase Agreement | Subsequent Event      
Line of Credit Facility [Line Items]      
Shares issued 950,750    
Purchase price per share $ 10.52    
Weighted average price days 30 days    
Proceeds from the issuance of ordinary shares $ 10,000    
Maximum aggregate right and offering participation amount $ 15,000    
Senior secured royalty notes      
Line of Credit Facility [Line Items]      
Initial face amount   $ 100,000  
Royalty percentage on global net sales   1.95%  
Aggregate purchase amount   $ 125,000  
Total funded amount recovery percentage   100.00%  
Senior secured royalty notes | Second purchase under royalty note purchase agreement      
Line of Credit Facility [Line Items]      
Aggregate value   $ 25,000  
Senior secured royalty notes | Third purchase under royalty note purchase agreement      
Line of Credit Facility [Line Items]      
Aggregate value   50,000  
Senior secured royalty notes | Upon approval of U.S. Food and drug administration or European medicines agency for bota-vec      
Line of Credit Facility [Line Items]      
Aggregate value   50,000  
Senior secured royalty notes | Upon approval of U.S. Food and drug administration for aav-haqp1      
Line of Credit Facility [Line Items]      
Aggregate value   50,000  
Senior secured royalty notes | Additional optional financing before December 31, 2028      
Line of Credit Facility [Line Items]      
Aggregate value   $ 100,000